William Mack & Associates
DGX icon

William Mack & Associates’s Quest Diagnostics DGX Stock Holding History

William Mack & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$700 Buy
+3
New +$693 ﹤0.01% 786

Other funds holding DGX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

William Mack & Associates's DGX Position: Q3 2026 in Review

William Mack & Associates opened a new position in Quest Diagnostics (DGX) in Q3 2026: 3 shares worth $700. The stake represents ﹤0.01% of the portfolio and ranks #786 among its holdings.

978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • William Mack & Associates held 3 shares of Quest Diagnostics worth $700 as of Q3 2026.
  • Quest Diagnostics was a new William Mack & Associates position in Q3 2026.
  • Quest Diagnostics made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #786 holding.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.